While blocking the EGF receptor by a mAb does not lead to clinical benefit so far, we hypothesized that EGFR remains a valid target for drug delivery systems in breast cancer, due to the high frequency and expression levels of EGFR on the surface of TNBC tumor cells. This evidence concerns the gene EGFR and breast carcinoma.